Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arvind Mathur

Showing results (91-100 of 148) with videos related to

Pageof 15
Sort By:
ACS Medicinal Chemistry Letters|January 15, 2025
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate ApproachYam B Poudel, Julian C Lo, Derek J Norris, et al.
ACS Medicinal Chemistry Letters|February 14, 2024
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncologyLiqi He, Meng Yao Zhang, Matthew Cox, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
The Journal of Organic Chemistry|September 7, 2017
Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097Arvind Mathur, Bei Wang, Daniel Smith, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal of Medicinal Chemistry|November 19, 2014
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activityJon J Hangeland, Todd J Friends, Karen A Rossi, et al.
Journal of Medicinal Chemistry|April 19, 2017
Selective I<sub>Kur</sub> Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamidePrashantha Gunaga, John Lloyd, Somanadham Mummadi, et al.
Journal of Medicinal Chemistry|February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|March 24, 2025
Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disordersDavid S Yoon, Shung Wu, Sean S Chen, et al.
Pageof 15

Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
ACS Medicinal Chemistry Letters|January 15, 2025
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate ApproachYam B Poudel, Julian C Lo, Derek J Norris, et al.
ACS Medicinal Chemistry Letters|February 14, 2024
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncologyLiqi He, Meng Yao Zhang, Matthew Cox, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
The Journal of Organic Chemistry|September 7, 2017
Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097Arvind Mathur, Bei Wang, Daniel Smith, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal of Medicinal Chemistry|November 19, 2014
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activityJon J Hangeland, Todd J Friends, Karen A Rossi, et al.
Journal of Medicinal Chemistry|April 19, 2017
Selective I<sub>Kur</sub> Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamidePrashantha Gunaga, John Lloyd, Somanadham Mummadi, et al.
Journal of Medicinal Chemistry|February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|March 24, 2025
Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disordersDavid S Yoon, Shung Wu, Sean S Chen, et al.
Pageof 15